Latest Security News

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

Loyal Metals has secured and begun unlocking value from the Highway Reward Copper-Gold Mine, revealing substantial unmined mineralisation and advancing lithium projects in North America.

Microba Life Sciences reports a 90% year-on-year increase in core microbiome test volumes, driving a 123% rise in core testing revenue to $2.1 million, while advancing clinical adoption and cost efficiencies.

First Graphene and UK manufacturer FP McCann have successfully produced the first batch of graphene-enhanced concrete roof tiles, marking a significant step toward low-carbon, high-performance construction materials in the UK housing sector.

Critical Resources Limited has secured a $1.75 million placement at market price, reinforcing investor confidence as it advances lithium, gold-antimony, and solid-state battery initiatives.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.

Genesis Minerals has restructured its executive team, appointing Raleigh Finlayson as Executive Chair and promoting Matthew Nixon to CEO, positioning the company for a significant growth phase.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

Arafura Rare Earths has raised A$481 million in equity funding and secured key government backing, advancing its Nolans Project towards a final investment decision in 2026.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.